BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
A Study in Healthy Volunteers Investigating How Quickly and to What Extent BAY1817080 is Taken up, Distributed, Broken Down and Eliminated From the Body, as Well as the Difference Between 2 Different Types of Tablets of BAY1817080 and the Difference Between Oral Dose and Dose in the Vein
Phase 1
Completed
- Conditions
- Biological Availability
- Interventions
- Drug: BAY1817080 - Formulation BDrug: BAY1817080 - Formulation ADrug: [13C715N]-BAY 181708 stable isotope label (SIL)
- First Posted Date
- 2018-12-12
- Last Posted Date
- 2019-08-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 30
- Registration Number
- NCT03773068
- Locations
- 🇳🇱
PRAHealthSciences, Groningen, Netherlands
Study to Find Out How Symptoms Severity Changes During the Standard Course of Treatment With the Cream Relief Pro and Suppositories Relief Pro (Active Ingredients Are Fluocortolone + Lidocaine) in Patients Suffering From Twisted and Bulging Veins in the Rectal Area (Acute Hemorrhoids)
Completed
- Conditions
- Acute Hemorrhoids
- Interventions
- Drug: Relief Pro creamDrug: Relief Pro rectal suppositories
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2020-10-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1000
- Registration Number
- NCT03757078
- Locations
- 🇷🇺
State Scientific Center of Coloproctology, Moscow, Russian Federation
This Study Tests the Safety of Inhaled BAY1237592, How the Drug is Tolerated and How it Effects Patients With High Blood Pressure in the Arteries of the Lungs in the Two Different Disease Groups Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Phase 1
Completed
- Conditions
- Hypertension, Pulmonary
- Interventions
- Drug: BAY1237592
- First Posted Date
- 2018-11-27
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 38
- Registration Number
- NCT03754660
- Locations
- 🇨🇿
Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia
🇦🇹Medizinische Universität Graz, Graz, Austria
🇨🇿Institut Klinicke a Experimentalni Mediciny, Praha 4, Czechia
Study on Medical Records of Women Using an Intrauterine Device (IUD) to Analyze the Risks That the IUD Will be Expelled or Perforates the Womb in Relation to Breastfeeding, the Point in Time When the IUD Was Inserted After Childbirth and in Relation to Different Types of IUDs
Completed
- Conditions
- Intrauterine Devices
- Interventions
- Device: Intrauterine device
- First Posted Date
- 2018-11-27
- Last Posted Date
- 2020-12-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 326658
- Registration Number
- NCT03754556
- Locations
- 🇺🇸
Kaiser Permanente Northern California, Oakland, California, United States
🇺🇸Kaiser Permanente Southern California, Pasadena, California, United States
🇺🇸Regenstrief Institute, Indianapolis, Indiana, United States
A Study Run At Multiple Study Sites to Test Whether the SAMANTA Questionnaire That is Used to Diagnose Heavy Menstrual Bleeding (HMB), Can Also Be Used to Assess Changes of Severity of HMB in Women with HMB Who Are Treated During 12 Months with a Chronic Hormonal Treatment
Completed
- Conditions
- Menorrhagia
- Interventions
- Drug: Chronic hormonal treatment
- First Posted Date
- 2018-11-23
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 422
- Registration Number
- NCT03751800
- Locations
- 🇪🇸
Many locations, Many locations, Spain
Study to Gain Insights in Treatment Patterns and Outcomes in Patients With Atherosclerosis Prescribed to Xarelto in Combination With Acetylsalicylic Acid
Completed
- Conditions
- Atherosclerosis
- Interventions
- Drug: Rivaroxaban (BAY59-7939, Xarelto)Drug: Acetylsalicylic acid
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 5798
- Registration Number
- NCT03746275
- Locations
- 🇬🇧
Multiple facilities, Multiple Locations, United Kingdom
Xarelto on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation
Completed
- Conditions
- Non-valvular Atrial Fibrillation (NVAF)
- Interventions
- Drug: Rivaroxaban(Xarelto,BAY 59-7939)
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2022-12-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 924
- Registration Number
- NCT03746301
- Locations
- 🇰🇷
Many locations, Multiple Locations, Korea, Republic of
EffectiveNess of Low-dose Aspirin in Prevention of Cancer in the Stomach and Oesophagus (GastrointEstinal Cancer Prevention) - United Kingdom ("ENgAGE - UK"): Study to Evaluate the Risk of Cancer in the Stomach and Oesophagus Among New Users of Low-dose Aspirin Using the THIN Database in the UK
Completed
- Conditions
- Prevention of Oesophagus Cancer and Stomach Cancer
- Interventions
- Drug: Acetylsalicylic Acid(BAYE4465, Aspirin )
- First Posted Date
- 2018-11-16
- Last Posted Date
- 2020-06-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 99999
- Registration Number
- NCT03743883
- Locations
- 🇬🇧
Many locations, Multiple Locations, United Kingdom
An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Non-small Cell Lung Cancer (NSCLC)Hepatocellular Carcinoma (HCC)Head and Neck Squamous Cell Carcinoma (HNSCC)
- Interventions
- First Posted Date
- 2018-11-08
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 16
- Registration Number
- NCT03735628
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers / Denver, CO, Denver, Colorado, United States
🇺🇸Tower Hematology/Oncology Medical Group, Beverly Hills, California, United States
🇺🇸Orthopaedic Institute for Children, Los Angeles, California, United States
Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer
Phase 1
Completed
- Conditions
- Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Interventions
- Drug: BAY2315497 InjectionDrug: Darolutamide(BAY1841788)
- First Posted Date
- 2018-10-30
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 63
- Registration Number
- NCT03724747
- Locations
- 🇺🇸
Tulane Medical Center, New Orleans, Louisiana, United States
🇬🇧Royal Marsden NHS Trust (Surrey), Sutton, Surrey, United Kingdom
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
© Copyright 2025. All Rights Reserved by MedPath